Biotech Values

[jbog]

It looks like the relapse rate of the FREEDOMS trial is in the same ballpark with Mercks Clarity trial.

FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%.

The Clarity trial showed that Claribine produced an 58% reduction in annualized relapse rates with the low dose and a 55% reduction with the high dose at 2 years.

Clarity also showed that over two years of study, 43% and 44% of patients treated with Cladribine Tablets (total dose of 3.5 mg/kg and 5.25 mg/kg respectively) had absence of disease activity which seems a little better than FTY720.